Published in Health Business Week, February 19th, 2010
"We describe the discovery and optimization of phenylacetamides as allosteric agonists of FFA2," wrote Y.C. Wang and colleagues, Amgen, Inc.
The researchers concluded: "These novel ligands can suppress adipocyte lipolysis in vitro and reduce plasma FFA levels in vivo, suggesting that these allosteric modulators can serve as pharmacological tools for exploring the potential function of FFA2 in various disease conditions."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week